BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid eye disease trial. Harbour BioMed...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...to advance therapies for genetic diseases. Promising programs may become additional BridgeBio affiliate companies.AbbVie in-licenses Harbour BioMed’s...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...HK$12.38 in its IPO. The deal gave the oncology and immunology antibody company, also known as Harbour BioMed...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...Plus: Harbour BioMed files to raise up to $230.4M in HK IPO By Virginia Li, Associate Editor ...
...in October to list on NASDAQ, withdrew its application on Nov. 13, citing market conditions.Meanwhile, Harbour BioMed...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...models.Few others have disclosed programs targeting CCR8. Harbour BioMed...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics Co. Ltd. and Harbour BioMed...
BioCentury | Jul 11, 2020
Finance

Harbour continues flurry of deals with $102.8M series C round

...of multiple COVID-19 mAb deals and a $75 million series B+ round closed in March, Harbour BioMed...
...well as Cambridge, Mass., has now raised more than $300 million to date. Virginia Li, Associate Editor Harbour BioMed...
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

...when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd., Harbour BioMed...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...to general partner from partner and Sarah Bhagat to partner from principal. Antibody discovery company Harbour BioMed...
BioCentury | Mar 12, 2020
Finance

Harbour backs first registrational trials with $75M B+ round

...in Cambridge, Mass., Rotterdam, Suzhou and Shanghai, has raised over $200 million to date (see “Harbour BioMed...
Items per page:
1 - 10 of 33
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid eye disease trial. Harbour BioMed...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...to advance therapies for genetic diseases. Promising programs may become additional BridgeBio affiliate companies.AbbVie in-licenses Harbour BioMed’s...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...HK$12.38 in its IPO. The deal gave the oncology and immunology antibody company, also known as Harbour BioMed...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...Plus: Harbour BioMed files to raise up to $230.4M in HK IPO By Virginia Li, Associate Editor ...
...in October to list on NASDAQ, withdrew its application on Nov. 13, citing market conditions.Meanwhile, Harbour BioMed...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...models.Few others have disclosed programs targeting CCR8. Harbour BioMed...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics Co. Ltd. and Harbour BioMed...
BioCentury | Jul 11, 2020
Finance

Harbour continues flurry of deals with $102.8M series C round

...of multiple COVID-19 mAb deals and a $75 million series B+ round closed in March, Harbour BioMed...
...well as Cambridge, Mass., has now raised more than $300 million to date. Virginia Li, Associate Editor Harbour BioMed...
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

...when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd., Harbour BioMed...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...to general partner from partner and Sarah Bhagat to partner from principal. Antibody discovery company Harbour BioMed...
BioCentury | Mar 12, 2020
Finance

Harbour backs first registrational trials with $75M B+ round

...in Cambridge, Mass., Rotterdam, Suzhou and Shanghai, has raised over $200 million to date (see “Harbour BioMed...
Items per page:
1 - 10 of 33